Clinical Spectrum of Children With Multisystem Inflammatory Syndrome Associated With SARS-CoV-2 Infection

JOLLY CHANDRAN,1 EBOR JACOB JAMES,1 VALSAN P VERGHESE,2 SATISH KUMAR T,3 KALA RANJINI SUNDARAVALLI E,1 SIVA VYASAM1

From1Pediatric Intensive Care Unit, 2Pediatric Infectious Diseases, and 3Pediatric Rheumatology, Department of Pediatrics, Christian Medical College, Vellore, Tamil Nadu.

Objectives: To compare the clinical profile, treatment, and outcomes of PCR-positive and PCR-negative antibody-positive critically ill children with multisystem inflammatory syndrome (MIS-C). Methods: This retrospective observational study was done at a tertiary care coronavirus disease 19 (COVID-19) pediatric intensive care unit in India. The baseline characteristics, clinical profile, treatment, and outcomes in seventeen critically ill children diagnosed with MIS-C were analyzed from 1 July to 31 October, 2020. Results: Sixteen out of 17 children presented with hypotensive shock and respiratory distress. Mean (SD) age of PCR-negative antibody-positive and PCR-positive children was 11 (4.4) and 5 (3.7) years, respectively (P=0.007). The former group had significantly higher mean (SD) D-dimer levels [16,651 (14859) ng/mL vs 3082 (2591) ng/mL; P=0.02]. All received intensive care management and steroid therapy; 7 children received intravenous immunoglobulin. 14 children survived and 3 died. Conclusions: The outcome of children with MIS-C was good if recognized early and received intensive care.

Keywords: COVID-19, Hypotensive shock, Respiratory distress, Steroids.
All children who were SARS-CoV-2 PCR positive or antibody positive fulfilling the MIS-C criteria were managed as per standard WHO treatment guidelines for critical disease including shock and ARDS (based on PaO2/FiO2 ratio and chest X-ray) [5], and the American College of Rheumatology (ACR) guidance on treatment of MIS-C [6], which included dexamethasone at 0.15 mg/kg/dose once daily and anticoagulant therapy with low molecular weight heparin (LMWH) at a dose of 0.5 mg/kg/dose twice daily in all children with D-dimer >500 ng/mL. Critically ill children on mechanical ventilation received unfractionated heparin at 5-10 units/kg/hour as an intravenous infusion for 24-48 hours till they were stable, which was then changed to LMWH. Intravenous immune globulin (IVIG) at a dose of 2 g/kg over 2 days was given to children with catecholamine-resistant shock and severe left ventricular dysfunction.

Statistical analysis: Statistical analysis was done using SPSS 23.0 (SPSS Inc.). Percentages and mean (standard deviations) were calculated for categorical and continuous variables, respectively. Independent sample t-test was used for comparing the means and two proportions test to compare the proportions between groups.

RESULTS

Over the study period, 415 children were admitted and screened for COVID-19 of whom 215 were admitted to COVID PICU (age range 1 month to 15 years). Thirty-six children (16%) were SARS-CoV-2 PCR positive, of whom 7 (19%) had moderate illness, 5 (14%) had severe and 24 (66%) had critical disease. Of the 24 children with critical disease, 10 (41%) had MIS-C. An additional 7 children with MIS-C were RT-PCR negative but COVID antibody-positive. Three PCR-positive infants aged one month, six months and 11 months had prematurity as a premorbid risk factor, and the 6 month old had also undergone Kasai procedure at 2 months of age for biliary atresia.

Clinical presentations were similar with fever in all and fluid-refractory hypotensive shock in 16 (75% of children being in cold shock) and respiratory distress in 16 children. The comparative clinical features between PCR-positive and PCR-negative antibody positive children are shown in Table I. Additional atypical manifestations seen in 2 children included refractory thrombocytopenia in a one-month-old infant and CNS stroke in a 6-year-old who had received steroids prior to admission and did not have respiratory distress or hypotensive shock at admission.

The antibody titre in 7 children who were PCR-negative by Siemens antibody test was >10 AU/mL in all. Roche analyses showed 5 out of 7 being positive with mean (SD) titres of 72.06 (38.3) while 2 of the children did not have the test done as there was inadequate sample for the second test. The comparative clinical and laboratory features between PCR-positive and PCR-negative antibody positive children are shown in Table I.

Blood cultures were sterile, dengue serology was negative, and scrub IgM ELISA was negative in all 17 children, ruling out other microbial causes. Twelve children had moderate-severe LV dysfunction, of whom seven were PCR-positive. Mild pericardial effusion was seen in two of the PCR-negative antibody positive children. Bedside echocardiographic screening showed no evidence of coronary artery ectasia or aneurysm.

Respiratory support was provided through HHFNC in 9 children (including 7 PCR-positive children), non-invasive ventilation in two PCR-positive children and invasive ventilation in five of whom four were PCR-
negative antibody positive children. There was evidence of acute respiratory distress syndrome (ARDS) in 8 children, with 4 each of PCR-positive and PCR-negative antibody positive children. Of these 8 children, two improved with non-invasive mechanical ventilation and one improved with heated humidified high flow nasal cannula therapy (HHHFNC), with the total duration of supplemental oxygen ranging from 3 to 5 days. The remaining five required invasive mechanical ventilation. Oxygenation Index ratio in three of these five children was >16, suggestive of severe ARDS. Inotropic support was needed for 14 children, with two inotropes (adrenaline and noradrenaline) needed in five of seven PCR-negative antibody positive children and six of ten PCR-positive children. Two children were treated with peripheral veno-arterial extra-corporeal membrane oxygenation (ECMO) for a period of 7 days for severe cardiac dysfunction with refractory shock. One child received continuous renal replacement therapy (CRRT) for acute kidney injury. All 17 received dexamethasone and 16 had anticoagulant therapy (except the one-month-old with refractory thrombocytopenia), and seven of the seventeen with catecholamine-resistant shock and severe LV dysfunction received intravenous immune globulin. None of the children received tocilizumab or investigational antiviral agents.

The mean duration of ICU stay was 7.3 (range 4 to 19) days. Fourteen (82%) children were discharged. Three children died during the study. One was a 1-month-old infant with refractory thrombocytopenia and multiorgan involvement treated with IVIG and a single dose of methylprednisolone at 30 mg/kg and cyclosporine for probable MAS (macrophage activation syndrome). Two others were adolescents with severe cardiac dysfunction, refractory shock and multiorgan failure, one of whom was on ECMO.

**DISCUSSION**

This series of seventeen children adds to the growing body of literature from India on manifestations, management and outcomes among critically ill COVID positive children with MIS-C associated with COVID-19 infection while only seven were COVID antibody positive, unlike most reports from Western countries where PCR-positivity in children with MIS-C is seen in about a-third [9,10]. The majority of children in this study had no major comorbidities comparable to studies from Italy and the US showing that children were mostly well prior to SARS-CoV-2 infection [10-12].

All the children were critically ill needing intensive care admission and inotropic support corresponding to earlier studies [11-13]. Although, they needed respiratory support, less than half of them required mechanical ventilation, similar to other studies that show that children with MIS-C have mild to moderate lung involvement, and that outcomes are good with appropriate respiratory support [11-13].

Within this cohort, children with only COVID-19 antibody positivity were older, and predominantly male. They presented with more gastrointestinal symptoms and had more severe lung involvement needing invasive mechanical ventilation, as well as special supportive therapy including ECMO in two children and CRRT in one child. Levels of inflammatory markers and cardiac enzymes were also higher in this group of children with higher mortality compared to those with PCR-positivity, suggesting that hyperinflammation and cytokine storm are more evident in those presenting later in SARS-CoV-2 infection, probably due to the presence of higher titres of IgG SARS-CoV-2 receptor binding domains that are associated with increased disease severity [14].

The mainstay of treatment in these children remains prompt identification and treatment with anti-inflammatory and immunosuppressive agents. Dexamethasone was given to all children as per the ACR guidance on treatment of MIS-C [6] and the lower mortality in patients on oxygen supplementation or ventilation as demonstrated in the RECOVERY trial [15]. IVIG has been suggested as the primary modality of therapy for MIS-C [6,10,11,13]. However, steroids are a promising option in the resource-limited setting which have shown to be equally effective in children with critical illness with good ICU care [8,11,13]. Larger studies would be beneficial to compare the effect of steroids alone or in combination with IVIG in the treatment of MIS-C.

As COVID-19 antibody testing was not available at our institution during the initial study period, it is possible that some PCR-negative cases of MIS-C may have been
missed. However, as none of the other children with critical illness during that period fulfilled the clinical diagnostic criteria for MIS-C, we feel it was probably minimal. Larger studies would be beneficial to compare the effect of steroids alone or in combination with IVIG in the treatment of MIS-C.

Acknowledgements: Drs. Najumal Hussain, Anna Simon and Leni Mathew were involved in the clinical care of patients studied. Dr. Grace Rebekah for her help in statistical analysis and Dr. Mahesh Moorthy, Clinical Virology for his help in providing the SARS-CoV-2 PCR and antibody levels.

Ethics clearance: Institutional Research Board, CMC Vellore; No. 13521, dated October 28, 2020.

Contributors: JC, EJJ: conception and design, acquisition of data, analysis and interpretation of data; JC, EJJ, VPV, SKT: drafting the article, revising it critically for important intellectual content; JC, EJJ, VPV, SKT, KR, SV: final approval of the version to be submitted and any revised version to be published.

Funding: None; Competing interests: None stated.

REFERENCES

1. Patnaik S, Behera JR, Nayak MK, et al. COVID-19 in children: Present and future perspective, an interim review. J Child Science. 2020;10:53-62.
2. Qiu H, Wu J, Hong L, et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: An observational cohort study. Lancet. 2020; 20:689-96.
3. Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020; 395:1607-8.
4. World Health Organization. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19. Scientific Brief 15 May 2020. Accessed on January 14, 2021. Available from: https://www.who.int/news-room/commentaries/detail/multisystem–inflammatory-syndrome-in-children-and-adolescents-with-covid-19
5. World Health Organization. Clinical Management of COVID-19. Interim Guidance 27 May 2020. Accessed on January 14, 2021. Available from https://apps.who.int/iris/bitstream/handle/10665/332196/WHO-2019-nCoV-clinical-2020.5-eng.pdf?sequence=1&isAllowed=y
6. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1. Arthritis Rheumatol. 2020;72: 1791-805.
7. Balasubramanian S, Nagendran TM, Ramachandran B, et al. Hyper-inflammatory syndrome in a child with COVID-19 treated successfully with intravenous immunoglobulin and tocilizumab. Indian Pediatr. 2020;57:681-3.
8. Jain S, Sen S, Lakshmivenkateshiah S, et al. Multisystem inflammatory syndrome in children with COVID-19 in Mumbai, India. Indian Pediatr. 2020;57:1015-9.
9. Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like Multisystem inflammatory syndrome in children during the COVID-19 pandemic in Paris, France: Prospective observational study. BMJ. 2020; m2094.
10. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study. Lancet. 2020; 395:1771-8.
11. Dufort EM, Koumans EH, Chow EJ, et al. Multisystem inflammatory syndrome in children in New York State. N Engl J Med. 2020;383:347-58.
12. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in US Children and Adolescents. N Engl J Med. 2020; 383:334-46.
13. Kaushik S, Aydin SI, Derespina KR, et al. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome Coronavirus 2 Infection (MIS-C): A multi-institutional study from New York City. J Pediatr. 2020;224:24-9.
14. Kaberdoss J, Pilania RK, Karkhele R, et al. Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: Immunological mechanisms, clinical manifestations and management. Rheumatol Int. 2021;41:19-32.
15. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384:693-704.